Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call January 28, 2026 8:00 AM EST
Company Participants
Christopher Stevo – Senior Vice President of Investor Relations & Competitive Intelligence
Richard Francis – President, CEO & Director
Eric Hughes – Executive VP of Global R&D and Chief Medical Officer
Eliyahu Kalif – Executive VP & CFO
Conference Call Participants
David Amsellem – Piper Sandler & Co., Research Division
Louise Chen – Scotiabank Global Banking and Markets, Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Jason Gerberry – BofA Securities, Research Division
Christopher Schott – JPMorgan Chase & Co, Research Division
Umer Raffat – Evercore ISI Institutional Equities, Research Division
Leszek Sulewski – Truist Securities, Inc., Research Division
Yuchen Ding – Jefferies LLC, Research Division
Presentation
Operator
Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q4 2025 Earnings Conference Call. My name is Alex, and I’ll be coordinating today’s call. [Operator Instructions] I’ll now hand over to Chris Stevo, SVP, Investor Relations. Please go ahead.
Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence
Thank you, Alex. Good morning, and good afternoon, everyone. Thank you for joining us on our fourth quarter call. Before I turn it over to our CEO, Richard Francis, I just want to remind everyone that we will be making forward-looking statements on this call. Any statements we make are only as of today, and we undertake no obligation to update those statements subsequently. And if you have any questions about our forward-looking statements, feel free to see the appropriate sections in our SEC Forms 10-K and 10-Q.
With that, Richard Francis.
Richard Francis
President, CEO & Director
Thank you, Chris. Good morning, good afternoon, everybody. Great to have you on the call. Also on the call with me today will be Dr. Eric Hughes, Head of R&D and Chief Medical Officer, who will be walking you through some exciting
